Literature DB >> 26643334

International Evaluation of MIC Distributions and Epidemiological Cutoff Value (ECV) Definitions for Fusarium Species Identified by Molecular Methods for the CLSI Broth Microdilution Method.

A Espinel-Ingroff1, A L Colombo2, S Cordoba3, P J Dufresne4, J Fuller5, M Ghannoum6, G M Gonzalez7, J Guarro8, S E Kidd9, J F Meis10, T M S C Melhem11, T Pelaez12, M A Pfaller13, M W Szeszs14, J P Takahaschi15, A M Tortorano16, N P Wiederhold17, J Turnidge18.   

Abstract

The CLSI epidemiological cutoff values (ECVs) of antifungal agents are available for various Candida spp., Aspergillus spp., and the Mucorales. However, those categorical endpoints have not been established for Fusarium spp., mostly due to the difficulties associated with collecting sufficient CLSI MICs for clinical isolates identified according to the currently recommended molecular DNA-PCR-based identification methodologies. CLSI MIC distributions were established for 53 Fusarium dimerum species complex (SC), 10 F. fujikuroi, 82 F. proliferatum, 20 F. incarnatum-F. equiseti SC, 226 F. oxysporum SC, 608 F. solani SC, and 151 F. verticillioides isolates originating in 17 laboratories (in Argentina, Australia, Brazil, Canada, Europe, Mexico, and the United States). According to the CLSI guidelines for ECV setting, ECVs encompassing ≥97.5% of pooled statistically modeled MIC distributions were as follows: for amphotericin B, 4 μg/ml (F. verticillioides) and 8 μg/ml (F. oxysporum SC and F. solani SC); for posaconazole, 2 μg/ml (F. verticillioides), 8 μg/ml (F. oxysporum SC), and 32 μg/ml (F. solani SC); for voriconazole, 4 μg/ml (F. verticillioides), 16 μg/ml (F. oxysporum SC), and 32 μg/ml (F. solani SC); and for itraconazole, 32 μg/ml (F. oxysporum SC and F. solani SC). Insufficient data precluded ECV definition for the other species. Although these ECVs could aid in detecting non-wild-type isolates with reduced susceptibility to the agents evaluated, the relationship between molecular mechanisms of resistance (gene mutations) and MICs still needs to be investigated for Fusarium spp.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26643334      PMCID: PMC4750715          DOI: 10.1128/AAC.02456-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  35 in total

Review 1.  Setting and revising antibacterial susceptibility breakpoints.

Authors:  John Turnidge; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2007-07       Impact factor: 26.132

2.  Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values.

Authors:  J Turnidge; G Kahlmeter; G Kronvall
Journal:  Clin Microbiol Infect       Date:  2006-05       Impact factor: 8.067

3.  Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species.

Authors:  S Arikan; M Lozano-Chiu; V Paetznick; S Nangia; J H Rex
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

4.  Multistate outbreak of Fusarium keratitis associated with use of a contact lens solution.

Authors:  Douglas C Chang; Gavin B Grant; Kerry O'Donnell; Kathleen A Wannemuehler; Judith Noble-Wang; Carol Y Rao; Lara M Jacobson; Claudia S Crowell; Rodlescia S Sneed; Felicia M T Lewis; Joshua K Schaffzin; Marion A Kainer; Carol A Genese; Eduardo C Alfonso; Dan B Jones; Arjun Srinivasan; Scott K Fridkin; Benjamin J Park
Journal:  JAMA       Date:  2006-08-23       Impact factor: 56.272

5.  Voriconazole treatment for less-common, emerging, or refractory fungal infections.

Authors:  John R Perfect; Kieren A Marr; Thomas J Walsh; Richard N Greenberg; Bertrand DuPont; Juliàn de la Torre-Cisneros; Gudrun Just-Nübling; Haran T Schlamm; Irja Lutsar; Ana Espinel-Ingroff; Elizabeth Johnson
Journal:  Clin Infect Dis       Date:  2003-04-22       Impact factor: 9.079

6.  Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions.

Authors:  Issam I Raad; Ray Y Hachem; Raoul Herbrecht; John R Graybill; Roberta Hare; Gavin Corcoran; Dimitrios P Kontoyiannis
Journal:  Clin Infect Dis       Date:  2006-04-11       Impact factor: 9.079

7.  Clinical and epidemiological aspects of infections caused by fusarium species: a collaborative study from Israel.

Authors:  Ran Nir-Paz; Jacob Strahilevitz; Mervyn Shapiro; Nathan Keller; Anna Goldschmied-Reouven; Oded Yarden; Colin Block; Itzhack Polacheck
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

8.  Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection.

Authors:  Marcio Nucci; Elias J Anaissie; Flavio Queiroz-Telles; Carlos A Martins; Plínio Trabasso; Cristiana Solza; Claudia Mangini; Belinda P Simões; Arnaldo L Colombo; Jorge Vaz; Carlos E Levy; Silvia Costa; Vaneusa A Moreira; José Salvador Oliveira; Nestor Paraguay; Gisele Duboc; Julio C Voltarelli; Angelo Maiolino; Ricardo Pasquini; Cármino A Souza
Journal:  Cancer       Date:  2003-07-15       Impact factor: 6.860

9.  Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies.

Authors:  Ana Espinel-Ingroff; Elizabeth Johnson; Hans Hockey; Peter Troke
Journal:  J Antimicrob Chemother       Date:  2008-01-25       Impact factor: 5.790

Review 10.  Fusarium infections in immunocompromised patients.

Authors:  Marcio Nucci; Elias Anaissie
Journal:  Clin Microbiol Rev       Date:  2007-10       Impact factor: 26.132

View more
  42 in total

1.  In Vitro Susceptibility of Fusarium to Isavuconazole.

Authors:  A Broutin; J Bigot; Y Senghor; A Moreno-Sabater; J Guitard; C Hennequin
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

2.  Multicenter, International Study of MIC/MEC Distributions for Definition of Epidemiological Cutoff Values for Sporothrix Species Identified by Molecular Methods.

Authors:  A Espinel-Ingroff; D P B Abreu; R Almeida-Paes; R S N Brilhante; A Chakrabarti; A Chowdhary; F Hagen; S Córdoba; G M Gonzalez; N P Govender; J Guarro; E M Johnson; S E Kidd; S A Pereira; A M Rodrigues; S Rozental; M W Szeszs; R Ballesté Alaniz; A Bonifaz; L X Bonfietti; L P Borba-Santos; J Capilla; A L Colombo; M Dolande; M G Isla; M S C Melhem; A C Mesa-Arango; M M E Oliveira; M M Panizo; Z Pires de Camargo; R M Zancope-Oliveira; J F Meis; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

Review 3.  Establishment and Use of Epidemiological Cutoff Values for Molds and Yeasts by Use of the Clinical and Laboratory Standards Institute M57 Standard.

Authors:  Shawn R Lockhart; Mahmoud A Ghannoum; Barbara D Alexander
Journal:  J Clin Microbiol       Date:  2017-02-15       Impact factor: 5.948

Review 4.  Therapeutic Challenges of Non-Aspergillus Invasive Mold Infections in Immunosuppressed Patients.

Authors:  Frederic Lamoth; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

5.  Potent Activities of Luliconazole, Lanoconazole, and Eight Comparators against Molecularly Characterized Fusarium Species.

Authors:  Mahdi Abastabar; Abdullah M S Al-Hatmi; Mohammad Vafaei Moghaddam; G Sybren de Hoog; Iman Haghani; Seyed Reza Aghili; Tahereh Shokohi; Mohammad Taghi Hedayati; Roshanak Daie Ghazvini; Reza Kachuei; Ali Rezaei-Matehkolaei; Koichi Makimura; Jacques F Meis; Hamid Badali
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

6.  Comparative Evaluation of Etest, EUCAST, and CLSI Methods for Amphotericin B, Voriconazole, and Posaconazole against Clinically Relevant Fusarium Species.

Authors:  Abdullah M S Al-Hatmi; Anne-Cécile Normand; Stephane Ranque; Renaud Piarroux; G Sybren de Hoog; Joseph Meletiadis; Jacques F Meis
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

7.  Phylogenetic Diversity and In Vitro Susceptibility Profiles of Human Pathogenic Members of the Fusarium fujikuroi Species Complex Isolated from South India.

Authors:  Ananya Tupaki-Sreepurna; Vijayakishore Thanneru; Sangeetha Natarajan; Savitri Sharma; Anjana Gopi; Murugan Sundaram; Anupma Jyoti Kindo
Journal:  Mycopathologia       Date:  2018-02-14       Impact factor: 2.574

8.  Fusarium Keratitis in Germany.

Authors:  Grit Walther; Serena Stasch; Kerstin Kaerger; Axel Hamprecht; Mathias Roth; Oliver A Cornely; Gerd Geerling; Colin R Mackenzie; Oliver Kurzai; Marie von Lilienfeld-Toal
Journal:  J Clin Microbiol       Date:  2017-07-26       Impact factor: 5.948

9.  Olorofim Susceptibility Testing of 1,423 Danish Mold Isolates Obtained in 2018-2019 Confirms Uniform and Broad-Spectrum Activity.

Authors:  Karen Marie Thyssen Astvad; Karin Meinike Jørgensen; Rasmus Krøger Hare; Raluca Datcu; Maiken Cavling Arendrup
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

10.  Pterostilbene, a Potential MCR-1 Inhibitor That Enhances the Efficacy of Polymyxin B.

Authors:  Yonglin Zhou; Shui Liu; Tingting Wang; Hui Li; Shusheng Tang; Jianfeng Wang; Yang Wang; Xuming Deng
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.